Cytokine and Chemokine Retention Profile in COVID-19 Patients with Chronic Kidney Disease

Chronic kidney disease (CKD) patients are more susceptible to infections compared to the general population. SARS-CoV-2 virus pathology is characterized by a cytokine storm responsible for the systemic inflammation typical of the COVID-19 disease. Since CKD patients have a reduced renal clearance, we decided to investigate whether they accumulate harmful mediators during the COVID-19 disease. We conducted a retrospective study on 77 COVID-19 hospitalized subjects in the acute phase of the illness. Thirteen different cytokines were assessed in plasma collected upon hospitalization. The patients were divided into three groups according to their estimated glomerular filtration rate, eGFR < 30 (n = 23), 30 < eGFR < 60 (n = 33), eGFR > 60 mL/min (n = 21). We found that Tumor Necrosis Factor α and its receptors I and II, Interleukin-7, Leukemia Inhibitory Factor, FAS receptor, Chitinase 3-like I, and the Vascular Endothelial Growth Factor showed an increased accumulation that negatively correlate with eGFR. Moreover, non-survivor patients with an impaired kidney function have significantly more elevated levels of the same mediators. In conclusion, there is a tendency in COVID-19 ESRD patients to accumulate harmful cytokines. The accumulation seems to associate with mortality outcomes and may be due to reduced clearance but also to increased biosynthesis in most severe cases.

[1]  T. Benfield,et al.  Prediction of Respiratory Failure and Mortality in COVID-19 Patients Using Long Pentraxin PTX3 , 2022, Journal of Innate Immunity.

[2]  A. Larsson,et al.  Soluble TNF receptors predict acute kidney injury and mortality in critically ill COVID-19 patients: A prospective observational study , 2021, Cytokine.

[3]  J. Berzofsky,et al.  IL-7 in SARS-CoV-2 Infection and as a Potential Vaccine Adjuvant , 2021, Frontiers in immunology.

[4]  Lanjuan Li,et al.  Cytokine Signature Associated With Disease Severity in COVID-19 , 2021, Frontiers in Immunology.

[5]  C. Ronco,et al.  Classification of Uremic Toxins and Their Role in Kidney Failure. , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[6]  A. Cossarizza,et al.  Cell Death in Coronavirus Infections: Uncovering Its Role during COVID-19 , 2021, Cells.

[7]  A. Mantovani,et al.  PTX3 Regulation of Inflammation, Hemostatic Response, Tissue Repair, and Resolution of Fibrosis Favors a Role in Limiting Idiopathic Pulmonary Fibrosis , 2021, Frontiers in Immunology.

[8]  M. Cozzolino,et al.  Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins , 2021, Toxins.

[9]  T. van der Poll,et al.  Pulmonary Procoagulant and Innate Immune Responses in Critically Ill COVID-19 Patients , 2021, Frontiers in Immunology.

[10]  J. Danesh,et al.  Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19 , 2021, medRxiv.

[11]  L. Rénia,et al.  Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients , 2021, Open forum infectious diseases.

[12]  B. Ma,et al.  Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19 , 2021, bioRxiv.

[13]  A. Avery,et al.  Levels of Soluble CD14 and Tumor Necrosis Factor Receptors 1 and 2 may be predictive of death in Severe Coronavirus Disease 2019 (COVID-19) , 2020, The Journal of infectious diseases.

[14]  R. Webby,et al.  Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes , 2020, Cell.

[15]  R. Vasan,et al.  Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. , 2020, Journal of the American Society of Nephrology : JASN.

[16]  L. Sağlam,et al.  Evaluation of alpha defensin, IL‐1 receptor antagonist, and IL‐18 levels in COVID‐19 patients with macrophage activation syndrome and acute respiratory distress syndrome , 2020, Journal of medical virology.

[17]  M. Ardalan,et al.  Covid‐19 and kidney injury: Pathophysiology and molecular mechanisms , 2020, Reviews in medical virology.

[18]  G. Erbaş,et al.  Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19 , 2020, Cytokine.

[19]  Kenneth G. C. Smith,et al.  Integrative Modeling of Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan Pathological Signature of SARS-CoV-2 Infection , 2020, Journal of proteome research.

[20]  R. Hotchkiss,et al.  Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19) , 2020, JAMA network open.

[21]  C. Peano,et al.  Macropahge expression and prognostic significance of the long pentraxin PTX3 in COVID-19 , 2020, medRxiv.

[22]  B. Zhu,et al.  Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China , 2020, The Journal of infectious diseases.

[23]  S. Metcalfe COVID-19 lockdown: de-risking exit by protecting the lung with leukaemia inhibitory factor (LIF) , 2020, Medicine in Drug Discovery.

[24]  E. Coomes,et al.  Interleukin‐6 in Covid‐19: A systematic review and meta‐analysis , 2020, medRxiv.

[25]  L. G. Vu,et al.  Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The Lancet.

[26]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[27]  R. Zemans,et al.  Transitional human alveolar type II epithelial cells suppress extracellular matrix and growth factor gene expression in lung fibroblasts. , 2019, American journal of physiology. Lung cellular and molecular physiology.

[28]  J. Barata,et al.  Flip the coin: IL-7 and IL-7R in health and disease , 2019, Nature Immunology.

[29]  M. Malaise,et al.  Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature , 2019, Rheumatology.

[30]  Cheng-Hsien Lu,et al.  α-1-Acid Glycoprotein Concentration as an Outcome Predictor in Adult Patients with Sepsis , 2019, BioMed research international.

[31]  F. Rieux-Laucat,et al.  FAS and RAS related Apoptosis defects: From autoimmunity to leukemia , 2018, Immunological reviews.

[32]  Ling Wang,et al.  Effects of interleukin‐7/interleukin‐7 receptor on RANKL‐mediated osteoclast differentiation and ovariectomy‐induced bone loss by regulating c‐Fos/c‐Jun pathway , 2018, Journal of cellular physiology.

[33]  G. Kaplanski Interleukin‐18: Biological properties and role in disease pathogenesis , 2017, Immunological reviews.

[34]  G. Hejblum,et al.  Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome , 2014, Arthritis & rheumatology.

[35]  R. Gress,et al.  An overview of IL-7 biology and its use in immunotherapy , 2010, Journal of immunotoxicology.

[36]  A. El-Agroudy,et al.  Soluble Fas: a useful marker of inflammation and cardiovascular diseases in uremic patients , 2010, Clinical and Experimental Nephrology.

[37]  Lorien S. Dalrymple,et al.  Epidemiology of acute infections among patients with chronic kidney disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[38]  Toshio Tanaka,et al.  T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN-γ and IL-13 production , 2007, Proceedings of the National Academy of Sciences.

[39]  J. Scheller,et al.  Interleukin-6 and its receptor: from bench to bedside , 2006, Medical Microbiology and Immunology.

[40]  J. Clark,et al.  What does tumour necrosis factor excess do to the immune system long term? , 2005, Annals of the rheumatic diseases.

[41]  T. Saruta,et al.  Leukemia inhibitory factor is involved in tubular regeneration after experimental acute renal failure. , 2003, Journal of the American Society of Nephrology : JASN.

[42]  M. Weiser,et al.  α1-Acid glycoprotein reduces local and remote injuries after intestinal ischemia in the rat. , 1997, American journal of physiology. Gastrointestinal and liver physiology.

[43]  P. Marik,et al.  Elevated serum levels of the type I and type II receptors for tumor necrosis factor-α as predictive factors for ARF in patients with septic shock , 2003 .